medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2009, Number 4

<< Back Next >>

Rev Mex Urol 2009; 69 (4)

Incidental prostate cancer prevalence in the Dr. Manuel Gea González General Hospital: a twenty-year review

Merayo-Chalico CE, Sánchez-Turati GJ, Santana-Ríos Z, Pérez-Becerra R, Saavedra-Briones DV, Morales-Montor JG, Pacheco-Gahbler C, Calderón-Ferro F

Language: Spanish
References: 22
Page: 147-152
PDF size: 151.20 Kb.


ABSTRACT

There are 185,000 new prostate cancer (CaP) cases reported annually and of those, depending on the series reviewed, 4-20% are incidental carcinomas. Prostate- specific antigen (PSA) is the most sensitive diagnostic method for identifying those patients with CaP probability. However, PSA levels can also be elevated in 16-86% of patients with benign prostatic hyperplasia (BPH).
Incidental prostate cancer (ICaP) is that which is unexpectedly found when examining, under microscope, resected tissue that has been diagnosed as benign.
The present study evaluated ICaP prevalence and identifiable risk factors in patients at our institution.
In a cross-sectional study, histopathology department case records of BPH patients having undergone either transurethral resection of the prostate (TURP) or open prostatectomy (OP) within the time frame of January 1988 to June 2008 were reviewed in order to identify ICaP cases.
There were a total of 953 BPH surgeries, 819 of which were TURP and 134 were OP. Mean age was 71 years and mean PSA was 5.8ng/dl. ICaP was found in 21 patients, resulting in a 2.20% prevalence.
In conclusion, ICaP is not a worldwide public health problem and it is reduced by adequate biopsy patient selection.


REFERENCES

  1. Fernández-Rosado E, Gómez Veiga F, Alvarez Castelo L, Ruibal Moldes M, Chantada Abal V, González Martín M. Clinicopathological study of incidental cancer prostate in patients undergoing surgery for symptomatic diagnosis of BPH. Actas Urol Esp 2006; 30(1):33-37.

  2. Napal Lecumberri S, Lameiro CousoFJ, Rubio Navarro C, Gómez Dorronsoro M, Larrinaga Liñero B, Ipiéns Aznar A. A study of the progression of the incidental prostate cancer depending on the kind of treatment performed. Actas Urol Esp 2007; 31(8):810-818.

  3. Herranz Amo F, Diez Cordero JM, Verdu Tartajo F, LLedo García E. Incidental Prostate Cancer. Actas Urol Esp 1999; 2(10):848-852.

  4. Brawer MK, Rennels MA, Nagle RB. Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy. Am J Clin Pathol 1989; 92:760-764.

  5. Lujan Galán M, García Tello A, Pascual Mateo C, Llanes González L, García Mediero JM, Ángulo Cuesta J, Berenguer Sánchez A. Prevalence and clinical meaning of focal and incidental prostate cancers. Actas Urol Esp 2007; 31(8):819-824.

  6. Núñez López A V, Ojea Calvo A, Domínguez Freire F, Rodríguez Iglesias B, Benavente Delgado J, Barros Rodríguez JM. Clinical and biological progression of incidental prostatic cancer (stage T1a). Actas Urol Esp 2003; 27(5):345-349.

  7. Picurelli Oltra, Sendra Torres, Fernández Rodriguez. Incidental prostatic adenocarcinoma in the era of the PSA. Actas Urol Esp 1997; 21:354-356.

  8. Van Andel, Vleeming R, Kurth K, de Reijke TM. Incidental carcinoma of the prostate. Semin Surg Oncol 1995; 11:36-45.

  9. Zigeuner RE, Lipsky K, Riedler I, Auprich M. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology 2003; 62:451-455.

  10. Kien T Mai, Phillip A Isotalo, Jerome Green, Garth Perkins. Incidental Prostatic adenocarcinomas and putative premalignant lesions in TURP specimens collected before and after the introduction of prostrate-specific antigen screening. Arch Pathol Lab Med 2000; 124:1454-1456.

  11. Argyropoulos A, Doumas K, Farmakis A, Aristas O. Characteristics of patients with stage T1b incidental prostate cancer. Scand J Urol Nephol. 2005; 39(4):289-93.

  12. Berner A. Harvei S, Skjorten. Follow-up of localized prostate cancer, with emphasis on previous undiagnosed incidental cancer. BJU International 1999; 83:47-52.

  13. Merrill RM. Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. Urol Oncol. 2002; 7(5):213-219.

  14. Bostwick DG. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 1992; 70(1):291-301.

  15. Abbas F, Hochberg D. Incidental prostatic adenocarcinoma in patients undergoing radical cystoprostatectomy for bladder cancer. Euro Urol. 1996; 30:322-326.

  16. Yin M, Bastacky S, Chandran U. Prevalence of incidental prostate cancer in the general population: A study of healthy organ donors. J Urol. 2008:179(3):892-895.

  17. American Joint Committee of Cancer (AJCC). Cancer Staging Manual, Sixth Edition, 2002.

  18. Alluaño C, Lopez M. Incidental prostatic cancer: T1a-T1b. Our experience after observation/radical surgery and literature review. Actas Urol Esp 2006;30(8):749-753.

  19. Robinson D, Aus G, Bak J, Gorecki T. Long-term follow-up of conservatively managed incidental carcinoma of the prostate: A multivariate analysis of prognostic factors. 2007;41(2):103-109.

  20. Masue N, Deguchi T, Nakano M, Ehara H. Retrospective study of 101 cases with incidental prostate cancer stages T1a and T1b. International J Urol. 2005;12(12):1045-1049.

  21. Rowe WJ, Laniado M, Walker M. Incidental acute prostatic inflammation is associated with a lower percentage of free prostate-specific antigen than other benign conditions of the prostate: A prospective screening study. BJU International 2006; 97:1039-1042.

  22. Solares ME, Soel J, Viveros JM, Rojas L, Pacheco C, Pérez R, Calderón F. Análisis de sobrevida en pacientes sometidos a prostatectomía radical, en población mexicana. Seguimiento a 5 años. Rev Mex Urol 2004;64:54-66.




2020     |     www.medigraphic.com